In conclusion, we have proposed AMPs‐based STING agonists and demonstrated a multi‐stimuli activatable peptide nanodrug (MAPN) to precisely activate the cGAS‐STING pathway and block PD‐1/PD‐L1 pathway for effective cancer immunotherapy. This evidence concerns the gene STING1 and cancer.